Hudson Bay Capital Management
VKTX icon

Hudson Bay Capital Management’s Viking Therapeutics VKTX Stock Holding History

Hudson Bay Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-150,000
Closed -$5.28M – 1613
2025
Q4 		$5.28M Buy
+150,000
New +$5.31M 0.02% 487
2025
Q1 		– Sell
-125,000
Closed -$5.03M – 1474
2024
Q4 		$5.03M Buy
+125,000
New +$7.13M 0.02% 499
2024
Q2 		– Sell
-50,000
Closed -$4.1M – 953
2024
Q1 		$4.1M Buy
+50,000
New +$2.22M 0.02% 341

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Hudson Bay Capital Management's VKTX Position: Q1 2026 in Review

Hudson Bay Capital Management sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 1,089 shares — an estimated $38.3K sold.

Hudson Bay Capital Management first reported a position in VKTX in Q1 2023 and held it in 3 quarters. The position peaked at $2.37M in Q3 2023. 412 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Hudson Bay Capital Management reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 1,089 Viking Therapeutics shares in Q1 2026, an estimated $38.3K.
  • Hudson Bay Capital Management first reported a position in Viking Therapeutics in Q1 2023 and held it in 3 quarters.
  • Hudson Bay Capital Management's Viking Therapeutics position peaked at $2.37M in Q3 2023.
  • 412 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.